research Development and validation of a patient‐reported outcome measure for hair loss treatment: The HAIR ‐Q
The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.
Search
for
Did you mean Patient-Reported Outcome Measures?
Sort by
Research
30 / 1000+ resultsresearch Development and validation of a patient‐reported outcome measure for hair loss treatment: The
research An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
Disease-specific tools better assess alopecia areata's impact on quality of life.
research PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA
No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
research Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Evaluating the accuracy of patient-reported hair outcomes versus trichometric measurements in PRP therapy
Patient-reported hair improvements align with actual hair density changes, not hair width.
research Alopecia Areata–Specific Patient-Reported Outcome Measures
research Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration
Choosing the right recall period for patient feedback is important for accurate data and depends on the disease, symptom changes, and patient impact.
research A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders
The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.
research Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.
research Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia
The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.
research Patient-reported outcomes, provider-reported outcomes, and physiologic parameters after gender-affirming hormone treatment in Canada: a systematic review
Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.
research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
research Patient experience in systemic lupus erythematosus: development of novel patient-reported symptom and patient-reported impact measures
New tools were created to help lupus patients report their symptoms and impacts more accurately.
research Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.
research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
research Patient prioritisation of items to develop the Patient‐Reported Impact of Dermatological Diseases measure: A global Delphi study
The study created a 27-item measure to assess the impact of skin diseases.
research The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome.
A new tool helps lupus patients and doctors better track symptoms and quality of life.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
research Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures
CLASI is a valid tool for assessing skin activity and damage in lupus patients.
research A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index
The Dermatology Life Quality Index is reliable and consistent but needs more diverse participant studies.
research Content validity of five single‐item instruments in adolescents with alopecia areata
The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.
research Combination therapy with injectable platelet-rich fibrin and microneedling for male androgenetic alopecia: an evaluation of current practice
Injectable platelet-rich fibrin with microneedling is safe and effective for male hair loss but less supported than other treatments.
research Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
research A new self‐reported measure of disease severity of scalp hair loss in alopecia areata
The new measure helps understand the personal and emotional impact of hair loss in alopecia areata patients.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research Facial Feminization: Systematic Review of the Literature
Facial feminization surgery is safe and patients are satisfied, but more detailed research is needed.